Shaping the future of the glucose monitoring industry has been at the forefront of Gluco-Chaser Inc’s missions. True to its mission, the company has optimized the relevant technologies for over a decade.

The advantages of Gluco-Chaser Inc’s platform technologies make Gluco-ChaserTM a primary leader in the huge and rapidly expanding market of glucose monitoring.


Gluco-ChaserTM employs a non-enzymatic electrochemical sensing scheme.

It is the first of its kind, and has long been optimized for mass production since its introduction through a highly cited journal publication.

The glucose detection mechanism and the corresponding electrode preparation methods are proprietary.


The followings are growing demands in the glucose sensor market.

Product Advantages


30 minute stabilization time : The Gluco-ChaserTM CGM sensor reduces initial stabilization to only 30 minutes upon sensor installment by using proprietary technology. This stabilization time stands as the shortest among current commercial CGMs, and this drastic time reduction is achieved through (1) simplifying an otherwise inefficient sensor installment procedure; (2) allowing users flexibility in how frequently the sensors are replaced -- made possible by the highly affordable Gluco-ChaserTM sensor.

Elimination of major interferents : The proprietary polymer membrane can preclude major well- known interferents such as acetaminophen and maltose that work against glucose sensors.

Calibration-free : This sensor remains stable for five days without calibration. Additionally, the sensor only requires factory calibration, unlike many CGMs which require finger-prick sensors for calibration.

Highly-competitive pricing : Unlike traditional glucose biosensors, Gluco-ChaserTM does not need a glucose-reactive enzyme, which is unstable and expensive. Our technology uses chemically and mechanically robust colloidal metal particles for signal transduction. This technology drastically lowers the manufacturing cost of the electrode, a key sensing component of the product.

Business Benefits

(1) Unlike most glucose sensors, Gluco-ChaserTM does not require an unstable and expensive enzyme for glucose detection.

(2) This leads to huge cost savings in production and storage of the core sensing components.

(3) Gluco-ChaserTM technology is applicable to various formats of glucose monitors from conventional BGM to short-term (8 ~ 48 hours) and long-term (3 ~ 7 days, and beyond) CGMs.

Usage Benefits

(1) Calibration-free operation of the sensor

(2) 30-Minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs)

(3) Affordable pricing, comparable to that of conventional finger-prick sensors

This package of features has yet to be implemented by current market leaders, making the Gluco-ChaserTM CGM a smarter choice for Type-2 as well as Type-1 patients.

Market Trends

Market Situation

BGM Market

Blood Glucose Monitoring (BGM)

$11~12 Billion Market in 2016 (10% annual growth) *

Finger-prick disposable sensors are the most common despite having technical limitations to managing glucose levels

Market demand is shifting to near real- time monitoring, using information technology

However, finger-prick disposables are hardly effective for real time monitoring

* www.businesswire.com

CGM Market

Continuous Glucose Monitoring (CGM)

$ ~1 Billion Market in 2016 (30% annual growth) *

Patch and needle type sensor

Ideal for real time monitoring

Originally developed for Type 1 Diabetes patients

Major efforts are being made to offer more affordable and easy-to-use CGM sensors for Type 2 diabetes patients (market size $20 Billion/year)

* www.alliedmarketresearch.com

Competition Landscape

The features of Gluco-ChaserTM CGM can be compared with major market leaders as follows.

DexCom G5® (Dexcom) Abbott Libre (Abbott) Minimed® (Medtronic) Accu-chek® (Roche) Gluco-ChaserTM
Glucose-responsive material Enzyme (GOx) Enzyme (GDH) Enzyme (GOx) Enzyme (GOx) Nanoporous Platinum
Time required for Initial stabilization 3 hrs 12 hrs 3 hrs instantly 0.5 hrs
Sensor Exchange Interval 7 days 10 days 5 days finger-prick 1 day   |   5 days
Calibration Free Yes Yes No Yes To be implemented
Elimination of Acetaminophen Interference No Yes No - Yes
Unit Price (USD) Main Unit 1200 135(2 units) 1200 - 70
Unit Price (USD) Disposable 90 70 95 20 3   |   10
Monthly Operation Cost (USD) 460 221 670 40 96   |   66

reader + transmitter [Go to Link1] [Go to Link1]

necessary due to long stabilization time [Go to Link]

transmitter + inserter

prices of 1 day   |   5 days

Growth and Scalability

Gluco-ChaserTM CGM is a Continuous Monitoring System that offers a solution to unmet market needs. Affordable and easy-to-use, our CGM is capable of managing type-2 as well as type-1 diabetes.

A prototype has been built using proprietary technologies and proven to be operable for up to 5 days by using a model animal.

An improved version of a prototype is currently being built based on animal testing results and will be implemented in human clinical trials in compliance with major market regulations.

Further efforts, including clinical trial and marketing, will be made in partnership with global companies and/or capitals.

Patents & Publications


Biosensor contained mesoporous platinum and method of determining concentration using same : KR 100481663 (2005.3.29)

Biosensor contained mesoporous platinum and method of determining concentration using same : US 7892415 (2011.2.22)

Fabrication of mesoporous metal electrodes in non-liquid-crystalline phase and its application : KR 100736252 (2007.6.29)

Measuring method of blood sugar level, apparatus and system thereof : KR 101288400 (2013.7.16)

Nanoporous Structure and Glucose-Sensing Device with Nanoporous Structure : US 15/844,479 (2017.12.15)

Method of Making a Colloid and Nanoporous Layer : US 15/844,484 (2017.12.15)

Non-Enzymatic Glucose-Sensing Device with Nanoporous Structure and Conditioning of the Nanoporous Structure : US 15/844,507 (2017.12.15)

Glucose-Sensing Device with Maltose Blocking Layer : US 15/844,515 (2017.12.15)

Glucose Sensor Apparatus Addressing Interference of Ascorbic Acid and Acetaminophen : US 15/845,668 (2017.12.15)

More patents coming soon…


Nonenzymatic Glucose Detection Using Mesoporous Platinum
Anal. Chem., 2003, 75 (13), pp 3046–3049. 535 times cited * [Go to Link]

Ionic Strength-Controlled Virtual Area of Mesoporous Platinum Electrode
J. Am. Chem. Soc., 2004, 126 (14), pp 4524–4525. 122 times cited * [Go to Link]

pH-Sensitive Solid-State Electrode Based on Electrodeposited Nanoporous Platinum
Anal. Chem., 2005, 77 (23), pp 7695–7701. 53 times cited * [Go to Link]

Electrochemical non-enzymatic glucose sensors
Analytica Chimica Acta, 2006, 556 (1), pp 46-57. 725 times cited * [Go to Link]

Electrochemical oxidation of hydrogen peroxide at nanoporous platinum electrodes and the application to glutamate microsensor
Electrochimica Acta, 2006, 52 (4), pp 1788-1791. 44 times cited * [Go to Link]

Three-Dimensional Interstitial Nanovoid of Nanoparticulate Pt Film Electroplated from Reverse Micelle Solution
Chem. Mater., 2007, 19 (14), pp 3373–3375. 44 times cited * [Go to Link]

Structural and electrochemical features of 3D nanoporous platinum electrodes
Electrochimica Acta, 2010, 55 (6), pp 2029-2035. 44 times cited 44 times cited * [Go to Link]

Effect of Nanoporous Structure on Enhanced Electrochemical Reaction
J. Phys. Chem. C, 2010, 114 (21), pp 9546–9553. 40 times cited * [Go to Link]

Nonenzymatic continuous glucose monitoring in human whole blood using electrified nanoporous Pt
Biosensors and Bioelectronics, 2012, 31 (1), pp 284-291. 42 times cited * [Go to Link]

Disposable Non-Enzymatic Blood Glucose Sensing Strip Based on Nanoporous Platinum Particles
Applied Materials Today, 2018, 10, pp 24-29. * [Go to Link]

* As of Nov. 8th, 2017 at WEB OF SCIENCETM


  • February 08, 2018 Gluco-Chaser™ Inc. Announces Disposable Glucose Sensor Results with Non-Enzymatic Electrochemistry.

    go to link →
  • November 21, 2017 Business Wire Gluco-Chaser™ Inc Releases a Working Prototype for Proprietary Non-Enzymatic Electrochemical Glucose Sensors Claiming a Multitude of Advantages(www.Gluco-Chaser.com).

    go to link →


Private Funding History

  • Jan 2016 Supported by angel investors, the seed funding round is closed.

  • Jan 2017 Series A funding is closed. Two venture capital companies (CKD Venture Capital Corp & MAGNA Investment Co., Ltd) are participants.

Corporate History

  • 2003 & 2004 Two monumental articles are published on the science and technology behind colloidal platinum electrode detection of glucose (see Patent & Publications section).

  • 2006 The company is founded by the lead authors of the publication to commercialize the technology.

  • 2012 The CGM sensor is operational without signal deterioration for one month while being immersed in human whole blood and human plasma.

  • Jan 2017 The company is launched in the USA (Redmond, WA) as Gluco-Chaser Inc.


How innovative is the Gluco-ChaserTM platform as a glucometer?

The founders of Gluco-Chaser Inc discovered in 2003 and 2004* that an aggregate of colloidal platinum particles are capable of detecting glucose on an electrode. They also showed that the platinum aggregate is a superior alternative to glucose-reactive enzymes used by current glucose biosensors, which fall short in in terms of the stability and the cost.
Every aspect of Gluco-ChaserTM technology is proprietary, including the processing of colloidal particles, the glucose detection scheme, and a variety of polymer coatings. Gluco-ChaserTM is a highly reliable platform offered at a remarkably affordable price-features that make it a potential primary leader in the glucose monitor market.

* publications cited more than 500- and 100 times, see the Publication page.

What are the advantages of Gluco-ChaserTM non-enzymatic electrochemical glucose sensor?

The advantages of Gluco-ChaserTM non-enzymatic electrochemical glucose sensor include: (1) the reliability of the sensor’s performance; (2) the low cost in production and long-term storage under temperature conditions harmful to enzymes, enabling affordable end user pricing; (3) short initiation time.

* 30 minutes taken compared with 3~12 hours of major market leaders.

What is the working principle of Gluco-ChaserTM non-enzymatic electrochemical glucose sensor?

An aggregate of colloidal platinum particles is loaded onto a printed electrode. The colloidal platinum particles oxidize glucose upon application of an electric potential, which then generates the electrical signal corresponding to the amount of glucose. This working principle of Gluco-ChaserTM sensor is an alternative to current glucose biosensors, most of which operate by immobilizing an expensive and hard-to-control glucose-responsive enzyme on an electrode.

Is the electrode preparation process for Gluco-ChaserTM manufacture compatible?

Yes, it can be manufacture-compatible. First, it is possible to scale up the processing  of colloidal particles. Also, it is also possible to load an aggregate of colloidal particles onto a patterned electrode in a reproducible manner at a high throughput.

What are other features unique to Gluco-ChaserTM technologies?

The sensor offers (1) calibration-free operation of the sensor*; (2) 30-minute window for initial stabilization (competitors range anywhere from 3 to 12 hrs); and (3) affordable pricing, comparable to that of conventional finger-prick sensors. This package of features has yet to be implemented by current market leaders, making the Gluco-ChaserTM CGM a smarter choice for Type-2 as well as Type-1 patients.
* Currently under development.

How frequently is the proposed non-enzymatic electrochemical glucose sensor replaced?

Gluco-ChaserTM CGM will offer two replacement interval options: short-term (1~2 days) and long-term (> 3 days). The short-term sensor replacement is made possible by the low cost and the Gluco-ChaserTM technology, drastically reducing the initiation time. As a result, user comfort level and hygiene are improved. As for the long-term interval option, Gluco-ChaserTM technology is currently comparable to that of major market leaders. However, development is underway to upgrade existing polymer coating to extend the operational life to as long as possible. In fact, Gluco-ChaserTM CGM sensor was operational without signal deterioration for one month while being immersed in human whole blood and human plasma.

How can you detect glucose from biofluids without use of an enzyme specifically reactive to glucose?

Currently, the Gluco-ChaserTM system is highly specific to glucose contained in body fluids. The system has been engineered in such a way that it can preclude the signals originating from major interferents (e.g. ascorbic acid, acetaminophen, and maltose) contained in body fluids.

What are the advantages of CGM over disposable finger-prick BGMs?

Real time monitoring of a glucose change is considered ideal for identification and management of diabetes. In this regard, CGM (Continuous Glucose Monitor) is much better at (1) judging whether one has diabetes; (2) identifying the pattern of the glucose change for timely insulin dose feed.

Is it possible to use a CGM (Continuous Glucose Monitor) for the management of type-2 diabetes? What are the pros and cons of doing so?

CGMs are generally known to be better for the management of type-1 diabetes, for which accurate insulin feed in response to glucose level change is imperative. Ideally the same criteria can be applied to the case of type-2 diabetes. However, many patients who are suffering from a less severe form of type-2 diabetes are likely to find it very cumbersome and costly to use current CGMs available in the market. Current CGMs are very uncomfortable to use, usually requiring 3~12 hours of installation in addition to wearing for longer than 5 days. Therefore, the CGM sensor system and its disposables may be too costly for these type-2 diabetics.

What is the developmental status of Gluco-ChaserTM CGM?

We have developed a prototype CGM, whose animal model glucose level results show an excellent match with those of a leading commercial finger-prick BGM sensor.

Why Gluco-Chaser CGMTM?

The onset of type-2 diabetes is hard to identify, and more than 40 % of type-2 patients are unaware of disease onset. Currently, identification of onset using commercial glucose monitors is difficult due to high costs and lack of user comfort. The Gluco-ChaserTM CGM is low-cost and easy-to-use, allowing users to evaluate their status quickly.  Our CGM is also the first ever in the market to provide quick installation as well as short-term replacement of sensor patches (See #6)

Why do you prioritize CGM over the BGM, even though the market size for the BGM is much bigger?

We are focusing more on Gluco-ChaserTM CGM simply because (1) Gluco-ChaserTM is able to address the huge, but unaddressed market to identify new type-2 patients; (2) there is a clear market trend that CGM, capable of real time monitoring, attempts to undertake the type 2 BGM market as an ideal form of glucose monitoring; (3) Gluco-ChaserTM technology has advantageous solutions to overcome the obstacles to such a shift in terms of the ease-of-use and the cost.

As of the current stage of development, however, it would take less cost and time to pursue commercialization of Gluco-ChaserTM BGM. Therefore, we are open to discussing such an opportunity regarding the Gluco-ChaserTM BGM.

Contact Us

Gluco-Chaser Inc. is currently seeking parties interested in further joint business development.
If you are interested in exploring opportunities for your specific needs,
contact contact@gluco-chaser.com, +1-408-650-4499